drugset / Trial / NCT01424826
The Effect of Intermittent Rifampicin on Raltegravir
Phase 1
Completed
18 enrolled
Helen Reynolds
Liverpool University Hospitals NHS Foundation Trust · collab
NaSingle-groupOpen-labelTreatment
Summary
This study seeks to address the question of whether intermittent dosing of rifampicin influences the pharmacokinetics of raltegravir when co-administered. This study aims to look at what happens when rifampicin is taken 3 times a week with the standard dose and an increased dose of raltegravir. This is to find out the best dose of raltegravir to take when taking rifampicin 3 times a week. The study will be conducted in 18 healthy volunteers.
Timeline
- Start
- 2012-01
- Primary completion
- 2013-06
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Raltegravir | Other / unclassified | 400 mg | — |
| Subject | Raltegravir | Other / unclassified | 800 mg | — |
| Subject | Rifampin | Small molecule | 600 mg | — |
| Subject | Rifampin | Small molecule | 900 mg | — |